— Shares of biopharmaceutical company AbbVie shed more than 1% after the CEO said at the JPMorgan Healthcare Conference that it expects the loss of exclusivity of Humira, its drug for
arthritis and psoriasis, to affect the company's performance in the near term, according to a report from Bloomberg. The company does not anticipate a decline in 2024 earnings, however.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States United States Latest News, United States United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Stocks making the biggest moves midday: Bed Bath & Beyond, Coinbase, Virgin Orbit and moreThese are the stocks posting the largest moves midday.
Source: CNBC - 🏆 12. / 72 Read more »
UBS sees these retail stocks winning from a potential Bed Bath & Beyond bankruptcyDoubts about Bed Bath & Beyond's future opens a door for other retailers to pick up market share, says UBS
Source: CNBC - 🏆 12. / 72 Read more »
Bed Bath & Beyond jumps 50% to lead last gasp rally in meme stocks; AMC gains 15%A group of highly speculative stocks rallied double digits on Wednesday as retail investors pushed meme names up again in the new year following a dismal 2022.
Source: CNBC - 🏆 12. / 72 Read more »